カテゴリー： 世界, 医療/バイオ, FactMR

世界の動脈硬化治療薬市場2023-2033：薬効分類別（抗血小板薬、コレステロール低下薬、βブロッカー、ACE阻害薬、カルシウム拮抗薬、利尿薬）、流通チャネル別（小売薬局、病院薬局、オンライン薬局）、地域別

【英語タイトル】Atherosclerosis Drugs Market Analysis, By Drug Class (Anti-platelet Medications, Cholesterol-lowering Medications, Beta Blockers, ACE Inhibitors, Calcium Channel Blockers, Diuretics), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Region - Global Market Insights 2023-2033

FactMRが出版した調査資料（FACT23AP081）・商品コード：FACT23AP081
・発行会社（調査会社）：FactMR
・発行日：2023年1月27日
・ページ数：約170
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧、印刷不可）USD4,500 ⇒換算￥684,000見積依頼/購入/質問フォーム
Global Site License（同一拠点内共有可）USD8,500 ⇒換算￥1,292,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Fact.MR社発行の最新調査レポートでは、世界の動脈硬化治療薬市場について2023年から2033年までの市場動向を分析・予測しています。当レポートは、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場展望、薬効分類別（抗血小板薬、コレステロール低下薬、フィブリン酸＆オメガ3脂肪酸誘導体、βブロッカー、その他）分析、流通チャネル別（小売薬局、病院薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況など、多面的な分析結果をまとめたものです。なお、企業情報として、GlaxoSmithKline Plc、Sanofi、Hoffmann-La Roche Ltdなどが含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・市場展望
・世界の動脈硬化治療薬市場規模：薬効分類別
　- 抗血小板薬の市場規模
　- コレステロール低下薬の市場規模
　- フィブリン酸＆オメガ3脂肪酸誘導体の市場規模
　- βブロッカーの市場規模
　- その他薬効分類の市場規模
・世界の動脈硬化治療薬市場規模：流通チャネル別
　- 小売薬局の市場規模
　- 病院薬局の市場規模
　- オンライン薬局の市場規模
・世界の動脈硬化治療薬市場規模：地域別
　- 北米の動脈硬化治療薬市場規模
　- ヨーロッパの動脈硬化治療薬市場規模
　- アジア太平洋の動脈硬化治療薬市場規模
　- 中南米の動脈硬化治療薬市場規模
　- 中東/アフリカの動脈硬化治療薬市場規模
・競争状況

本レポートには、各企業の製品ポートフォリオや主要戦略、包括的なSWOT分析などの要素を含む企業情報が含まれています。企業のプレゼンスは、全著名プレーヤーについてマッピングされ、マトリックスを通して提示されます。また、購読者に実用的な洞察を提供し、熟考して市場の状況を示し、動脈硬化治療薬における競争レベルを推測するのに役立ちます。

Atherosclerosis Drugs Market – Scope of Report

A recent study by Fact.MR on the atherosclerosis drugs market offers a 10-year forecast for 2023 to 2033. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering atherosclerosis drugs.

The study also provides the dynamics responsible for influencing the future status of the atherosclerosis drugs market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the atherosclerosis drugs market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of atherosclerosis drugs across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of atherosclerosis drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of value (US$ Mn).

Estimates at global and regional levels for atherosclerosis drugs are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.

Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global atherosclerosis drugs market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the atherosclerosis drugs market during the forecast period.

Country-specific valuation on demand for atherosclerosis drugs has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition

The report sheds light on leading manufacturers of atherosclerosis drugs, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering atherosclerosis drugs has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the atherosclerosis drugs domain.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

            4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases

            4.3.1.2. Development of New Treatments

            4.3.1.3. Rising Awareness about Cardiovascular Diseases

        4.3.2. Restraints

            4.3.2.1. Availability of Generic Products

            4.3.2.2. Low Diagnostic Rate

        4.3.3. Opportunities

    4.4. Global Market Analysis and Forecast, 2023–2033

5. Market Outlook

    5.1. Clinical Trial Pipeline Analysis

    5.2. Disease Prevalence & Incidence Rate globally with key countries

    5.3. Brand Analysis

6. Global Market Analysis and Forecast, By Drug Class

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        6.2.1. Anti-platelet Medications

        6.2.2. Cholesterol Lowering Medications

        6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        6.2.4. Beta Blockers

        6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        6.2.6. Calcium Channel Blockers

        6.2.7. Diuretics

        6.2.8. Others

    6.3. Global Market Attractiveness, by Drug Class

7. Global Market Analysis and Forecast, By Distribution Channel

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        7.2.1. Retail Pharmacies

        7.2.2. Hospital Pharmacies

        7.2.3. Online Pharmacies

    7.3. Global Market Attractiveness, by Distribution Channel

8. Global Market Analysis and Forecast, By Region

    8.1. Key Findings

    8.2. Global Market Revenue (US$ Mn) Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Global Market Attractiveness, by region

9. North America Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        9.2.1. Anti-platelet Medications

        9.2.2. Cholesterol Lowering Medications

        9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        9.2.4. Beta Blockers

        9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        9.2.6. Calcium Channel Blockers

        9.2.7. Diuretics

        9.2.8. Others

    9.3. North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        9.3.1. Retail Pharmacies

        9.3.2. Hospital Pharmacies

        9.3.3. Online Pharmacies

    9.4. North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Market Attractiveness

        9.5.1. By Drug Type

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        10.2.1. Anti-platelet Medications

        10.2.2. Cholesterol Lowering Medications

        10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        10.2.4. Beta Blockers

        10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        10.2.6. Calcium Channel Blockers

        10.2.7. Diuretics

        10.2.8. Others

    10.3. Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        10.3.1. Retail Pharmacies

        10.3.2. Hospital Pharmacies

        10.3.3. Online Pharmacies

    10.4. Europe Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2023–2033

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Market Attractiveness

        10.5.1. By Drug Type

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-region

11. Asia Pacific Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        11.2.1. Anti-platelet Medications

        11.2.2. Cholesterol lowering medications

        11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        11.2.4. Beta blockers

        11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        11.2.6. Calcium Channel Blockers

        11.2.7. Diuretics

        11.2.8. Others

    11.3. Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        11.3.1. Retail Pharmacies

        11.3.2. Hospital Pharmacies

        11.3.3. Online Pharmacies

    11.4. Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Market Attractiveness

        11.5.1. By Drug Type

        11.5.2. By Distribution Channel

        11.5.3. By Country/Sub-region

12. Latin America Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        12.2.1. Anti-platelet Medications

        12.2.2. Cholesterol Lowering Medications

        12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        12.2.4. Beta blockers

        12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        12.2.6. Calcium Channel Blockers

        12.2.7. Diuretics

        12.2.8. Others

    12.3. Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        12.3.1. Retail Pharmacies

        12.3.2. Hospital Pharmacies

        12.3.3. Online Pharmacies

    12.4. Latin America Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Market Attractiveness

        12.5.1. By Drug Type

        12.5.2. By Distribution Channel

        12.5.3. By Country/Sub-region

13. Middle East & Africa Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

        13.2.1. Anti-platelet medications

        13.2.2. Cholesterol Lowering Medications

        13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

        13.2.4. Beta blockers

        13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors

        13.2.6. Calcium Channel Blockers

        13.2.7. Diuretics

        13.2.8. Others

    13.3. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

        13.3.1. Retail Pharmacies

        13.3.2. Hospital Pharmacies

        13.3.3. Online Pharmacies

    13.4. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

        13.4.1. GCC

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Market Attractiveness

        13.5.1. By Drug Type

        13.5.2. By Distribution Channel

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Key Company’s Market Ranking Analysis

    14.3. Company Profiles

        14.3.1. GlaxoSmithKline Plc

            14.3.1.1. Company Overview

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Sanofi

            14.3.2.1. Company Overview

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. Hoffmann-La Roche Ltd

            14.3.3.1. Company Overview

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Bayer AG

            14.3.4.1. Company Overview

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Novartis AG

            14.3.5.1. Company Overview

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

            14.3.6.1. Company Overview

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

            14.3.7.1. Company Overview

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Mylan N.V.

            14.3.8.1. Company Overview

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Amgen Inc.

            14.3.9.1. Company Overview

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

        14.3.10. Pfizer, Inc.

            14.3.10.1. Company Overview

            14.3.10.2. Company Financials

            14.3.10.3. Growth Strategies

            14.3.10.4. SWOT Analysis

Table 01: Atherosclerosis Pipeline Analysis

Table 02: Atherosclerosis Pipeline Analysis

Table 03: Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

Table 04: Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 05: Global Market Revenue (US$ Mn) Forecast, by Region, 2023–2033

Table 06: North America Market Revenue (US$ Mn) Forecast, by Drug Class 2023–2033

Table 07: North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 08: North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033

Table 09: Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

Table 10: Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 11: Europe Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 12: Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

Table 13: Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 14: Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 15: Latin America Market Revenue (US$ Mn) Forecast, by Drug Class 2023–2033

Table 16: Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 17: Latin America Market Revenue (US$ Mn) Forecast, by Country / Sub-region, 2023–2033

Table 18: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033

Table 19: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 20: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

★調査レポート[世界の動脈硬化治療薬市場2023-2033：薬効分類別（抗血小板薬、コレステロール低下薬、βブロッカー、ACE阻害薬、カルシウム拮抗薬、利尿薬）、流通チャネル別（小売薬局、病院薬局、オンライン薬局）、地域別] (コード：FACT23AP081)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の動脈硬化治療薬市場2023-2033：薬効分類別（抗血小板薬、コレステロール低下薬、βブロッカー、ACE阻害薬、カルシウム拮抗薬、利尿薬）、流通チャネル別（小売薬局、病院薬局、オンライン薬局）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のアテローム性動脈硬化症治療薬市場2023年-2032年：薬剤種類別（抗血小板薬＆抗凝固薬、コレステロール低下薬、ACE阻害薬、その他）、投与経路別（経口、注射）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア＆小売薬局）
  • 世界のペプチド感染症治療薬市場2023-2033：治療薬別（テラプレビル、ボセプレビル）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界のペプチドベース心臓血管治療薬市場2023-2033：治療薬別（ビバリルジン、エプチフィバチド）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界の制酸薬市場2023-2033：薬物クラス別（プロトンポンプ阻害剤、H2アンタゴニスト、酸性中和剤）、製剤別（錠剤、液体、粉末）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界のペプチド治療薬（メタボリックシンドローム用）市場2023-2033：治療薬別（リラグルチド、エキセナチド）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界の神経障害性疼痛市場2023年-2032年：薬効分類別（抗うつ薬、抗けいれん薬、オピオイド、カプサイシン、その他）、疾患別（糖尿病性神経障害、脊柱管狭窄症、化学療法誘発性末梢神経障害、その他）、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン薬局）
  • 世界の血栓溶解薬市場2023年-2032年：製品別（血栓溶解薬、抗血小板薬、抗凝固薬、その他）、疾患別（肺塞栓症、深部静脈血栓症、心房細動、その他）、投与経路別（経口、注射）、流通チャネル別（病院薬局、オンライン薬局、小売薬局）
  • 世界のプレフィルドオートインジェクター（薬剤充填済み自動注射器）市場2023-2033：疾患別（アナフィラキシー、多発性硬化症、関節リウマチ）、流通チャネル別（病院薬局、小売薬局、オンライン薬局、ドラッグストア）、地域別
  • 世界の気管支喘息治療市場2023-2033：治療薬別（長期喘息治療薬、即効性喘息治療薬）、投与経路別（吸入、経口、静脈内、皮下）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 世界のペグフィルグラスチムバイオシミラー市場2023-2033：用途別（化学療法治療、移植）、流通チャネル別（病院薬局、小売薬局、通信販売/オンライン薬局）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆